Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Rapid Infusion Daratumumab Is Safe in Patients with AL Amyloidosis

Nathaniel Rosko, PharmD, Hanjie Mo, PharmD, Joslyn Rudoni, PharmD, Caitlin Siebenaller, PharmD, Sarah S Lee, MD, Rajshekar Chakraborty, MD, Beth M. Faiman, PhDCNP, Jack Khouri, MD, Alex V. Mejia Garcia, MD, Christy J. Samaras, DO, Faiz Anwer, MD, Jason Valent, MD

Blood (2019) 134 (Supplement_1): 1838.

https://doi.org/10.1182/blood-2019-124775

Published: 2019

Journal Articles

A Phase IIa, Open-Label, Multicenter Study of Single-Agent Tafasitamab (MOR208), an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma: Long-Term Follow-up, Final Analysis

Wojciech Jurczak, MD PhD, Pier Luigi Zinzani, MD PhD, Georg Hess, Gianluca Gaidano, MD PhD, Mariano Provencio, MD, Zsolt Nagy, MD PhD, Tadeusz Robak, MD, Kami J. Maddocks, MD, Christian Buske, MD PhD, Sumeet Ambarkhane, MD MBBS, Wolfram Brugger, Maren Dirnberger-Hertweck, PhD, Sascha Tillmanns, Johannes Weirather, PhD, Kristie Blum

Blood (2019) 134 (Supplement_1): 4078.

https://doi.org/10.1182/blood-2019-124297

Published: 2019

Journal Articles

First-in-Human, Phase 1/2 Trial to Assess the Safety and Clinical Activity of Subcutaneous GEN3013 (DuoBody ® -CD3×CD20) in B-Cell Non-Hodgkin Lymphomas

Pieternella Lugtenburg, MD PhD, Rogier Mous, MD PhD, Michael Roost Clausen, Martine E.D. Chamuleau, Peter Johnson, MDFRCP, Kim Linton, PhD, Simon Rule, Roberto S Oliveri, MD PhD, Dena DeMarco, Ida H Hiemstra, PhD, Guang Chen, Ada Azaryan, Manish Gupta, Tahamtan Ahmadi, Martin Hutchings, MD PhD

Blood (2019) 134 (Supplement_1): 758.

https://doi.org/10.1182/blood-2019-121460

Published: 2019

Journal Articles

Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2:2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Peter Westervelt, MD PhD, Jorge E. Cortes, MD, Jessica K. Altman, Meixiao Long, MD, Vivian G. Oehler, MD, Ivana Gojo, MD, Jeanmarie Guenot, PhD, Patrick Chun, MD, Gail J. Roboz, MD

Blood (2019) 134 (Supplement_1): 834.

https://doi.org/10.1182/blood-2019-129042

Published: 2019

Journal Articles

Evaluation of Infusion Reactions in Patients Receiving Daratumumab Post-Implementation of an Augmented Pre- and Peri-Medication Regimen

Patrick McBride, PharmD, Houry Leblebjian, PharmD, Paul Richardson, Jacob Laubach, MD, Hillary Prescott, PharmD

Blood (2018) 132 (Supplement 1): 3234.

https://doi.org/10.1182/blood-2018-99-111361

Published: 2018

Journal Articles

Tocilizumab to Prevent Infusion-Related Events in Patients with Chronic Lymphocytic Leukemia and Co-Morbidities Treated with Obinutuzumab and Chlorambucil: Results from the Randomized Phase Ib GALACTA Trial

Ciara Louise Freeman, MRCP, MSc, FRCPath, MBBChir, Sebastian Böttcher, Javier De la Serna, Julio Delgado, Franca Falzetti, Marco Gobbi, MD, Sandra Lejniece, Maria Chiara Di Bernardo, Navita L Mallalieu, Tina Nielsen, Andrea Knapp, John G. Gribben

Blood (2018) 132 (Supplement 1): 4419.

https://doi.org/10.1182/blood-2018-99-118238

Published: 2018

Journal Articles

Acetaminophen Caused Transfusion Dependent Children Repeated Hepatitis

Ching-Tien Peng, MD MPH, Chien-Yu Lin, Kang-Hsi Wu, Tefu Weng, Jan-Gowth Chang, Wan-Yu Lo

Blood (2017) 130 (Supplement 1): 4930.

https://doi.org/10.1182/blood.V130.Suppl_1.4930.4930

Published: 2017

Journal Articles

Activity and Safety of Daratumumab Monotheray in Patients with Relapsed and Refractory Multiple Myeloma Requiring Dialysis: Preliminary Results of Spanish, Retrospective, Multicenter Trial

Maria José Cejalvo, Mario Legarda, Eugenia Abella, Elena Cabezudo, Cristina Encinas, Ana García-Feria, Belén Iñigo, Jesús Marín, Paz Ribas, M. Ángeles Ruíz, Javier de la Rubia

Blood (2017) 130 (Supplement 1): 1866.

https://doi.org/10.1182/blood.V130.Suppl_1.1866.1866

Published: 2017

Journal Articles

Phase 1 Clinical Trial of Adoptive Immunotherapy Using "Off-the-Shelf" Activated Natural Killer Cells (aNK) in Patients with Refractory/Relapsed Acute Myeloid Leukemia

Michael Boyiadzis, MD MHSc, Mounzer Agha, MD, Robert L Redner, MD, Alison Sehgal, MD, Annie Im, MD, Jing-Zhou Hou, Rafic Farah, MD, Kathleen A. Dorritie, MD, Anastasios Raptis, MD PhD, Seah H. Lim, MDPhDFRCP,FRCPath,MBBS, Hans Klingemann, MD PhD, Hong Wang, PhD, Natalia Lapteva, PhD, Mei Zhuyong, MD, Lisa H Butterfield, PhD, Cliona M. Rooney, PhD, Theresa L Whiteside, PhD

Blood (2016) 128 (22): 1649.

https://doi.org/10.1182/blood.V128.22.1649.1649

Published: 2016

Journal Articles

Decreased Rates of Severe CRS Seen with Early Intervention Strategies for CD19 CAR-T Cell Toxicity Management

Rebecca Gardner, MD, Kasey J Leger, MD MSc, Colleen E. Annesley, MD, Corinne Summers, MD, Julie Rivers, MD, Juliane Gust, MD, Katherine Tarlock, MD, Todd M Cooper, DO, Navin R. Pinto, MD, Olivia Finney, PhD, Hannah Smithers, MS, Assaf Oron, PhD, Daniel Li, PhD, Julie R Park, MD, Michael C Jensen, MD

Blood (2016) 128 (22): 586.

https://doi.org/10.1182/blood.V128.22.586.586

Published: 2016

Journal Articles

Rescue of a Terminally Ill Patient with Chemo-Refractory Acute Lymphoblastic Leukemia Carrying Bcr/Abl and TP53 Mutations Based on a 4th Generation CD19 Chimeric Antigen Receptor-Engineered T (CAR-T) Therapy

Ting Niu, MD PhD, Lung-Ji Chang, PhD, Jinrong Yang, MD, Yuchen Liu, MSc, Lujia Dong, MD, Wei Wang, PhD, Ting Liu, MD

Blood (2015) 126 (23): 5431.

https://doi.org/10.1182/blood.V126.23.5431.5431

Published: 2015

Journal Articles

An Update On The Clinical Activity Of Resimmune, a Targeted Therapy Directed To CD3 Receptor, In Patients With Cutaneous T Cell Lymphomas--CTCL

Arthur E. Frankel, MD, Jung H Woo, PhD, Jeremy P Mauldin, PhD, Francine M. Foss, MD, Madeleine Duvic, MD, David M Neville, Jr., MD

Blood (2013) 122 (21): 4381.

https://doi.org/10.1182/blood.V122.21.4381.4381

Published: 2013

Journal Articles

Open-Label Bendamustine Combined with Rituximab for Treatment of Relapsed/Refractory Mantle-Cell Lymphoma: Efficacy and Safety Findings

Myron S. Czuczman, MD, Dominick Lamonica, MD, Shari K. Gaylor, Leonard Bush, BHS, Penny Nadolny, Dave Colborn

Blood (2012) 120 (21): 3662.

https://doi.org/10.1182/blood.V120.21.3662.3662

Published: 2012

Journal Articles

Selective Splenic Artery Embolization for the Treatment of Thrombocytopenia and Hypersplenism in Paroxysmal Nocturnal Hemoglobinuria (PNH)

Anna Paola Iori, Karen Brown, David J. Araten, Emilia Scalzulli, Giovanni Fernando Torelli, Maria Stefania De Propris, Corrado Girmenia, Filippo Maria Salvatori, Orly Zelig, Robin Foa, MD, Lucio Luzzatto

Blood (2012) 120 (21): 4408.

https://doi.org/10.1182/blood.V120.21.4408.4408

Published: 2012

Journal Articles

Risk Factors for Infectious Complications in Adults with Acute Myeloid Leukemia Undergoing Induction Chemotherapy

Patrick Bruck, Thomas Parnavas, Dieter Hoelzer, MD, PhD, Hubert Serve, Oliver G. Ottmann, MD, Angelika Boehme

Blood (2008) 112 (11): 4043.

https://doi.org/10.1182/blood.V112.11.4043.4043

Published: 2008

Journal Articles

Effects of Imatinib on the Pharmacokinetics of Acetaminophen in Korean Patients with Chronic Myelogenous Leukemia (CML)

Dong-Wook Kim, MD, PhD, Sa-Hee Park, Yu Jin, MS, Michael Hayes, PhD, Yanfeng Wang, PhD

Blood (2008) 112 (11): 5056.

https://doi.org/10.1182/blood.V112.11.5056.5056

Published: 2008

Journal Articles

Activity and Safety of Combined Fludarabine and Alemtuzumab Followed by Low-Dose Alemtuzumab Maintenance Therapy in Patients with B-CLL.

Malgorzata Kowal, Anna Dmoszynska

Blood (2006) 108 (11): 4993.

https://doi.org/10.1182/blood.V108.11.4993.4993

Published: 2006

Journal Articles

Combined Schedule of Fludarabine and Alemtuzumab Followed by Maintenance with Low-Dose Alemtuzumab Is Effective for Patients with Progressive B-Cell Chronic Lymphocytic Leukemia.

Malgorzata Kowal, Wieslaw Nowak, Aleksandra Nowaczynska, Anna Dmoszynska, Aleksander B. Skotnicki

Blood (2005) 106 (11): 5048.

https://doi.org/10.1182/blood.V106.11.5048.5048

Published: 2005

Journal Articles

Interaction between Paracetamol and Warfarin: A Double-Blind Placebo-Controlled Randomised Study.

Isabelle Mahe, MD, PhD, Nathalie Bertrand, MD, Ludovic Drouet, MD, PhD, Guy Simoneau, MD, Claire Bal dit Sollier, MD, Elizabeth Mazoyer, MD, Charles Caulin, MD, Jean-François Bergmann, MD

Blood (2005) 106 (11): 4153.

https://doi.org/10.1182/blood.V106.11.4153.4153

Published: 2005

Journal Articles

Chimeric Anti CD-20 Monoclonal Antibody-Rituximab in Refractory Childhood Idiopathic Thrombocytopenic Purpura: An Indian Experience.

Ajay Sharma, MD, Velu Nair, MD, Deepak K. Mishra, MD, Jyoti Kotwal, MD, Gurvinder S. Chopra, MD, PhD, N. K. Bhandari, MD, Mohan B. Agarwal, MD, Ramji Rai, MD

Blood (2005) 106 (11): 4010.

https://doi.org/10.1182/blood.V106.11.4010.4010

Published: 2005

NARROW

Rapid Infusion Daratumumab Is Safe in Patients with AL Amyloidosis

A Phase IIa, Open-Label, Multicenter Study of Single-Agent Tafasitamab (MOR208), an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma: Long-Term Follow-up, Final Analysis

First-in-Human, Phase 1/2 Trial to Assess the Safety and Clinical Activity of Subcutaneous GEN3013 (DuoBody ® -CD3×CD20) in B-Cell Non-Hodgkin Lymphomas

Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2:2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Evaluation of Infusion Reactions in Patients Receiving Daratumumab Post-Implementation of an Augmented Pre- and Peri-Medication Regimen

Tocilizumab to Prevent Infusion-Related Events in Patients with Chronic Lymphocytic Leukemia and Co-Morbidities Treated with Obinutuzumab and Chlorambucil: Results from the Randomized Phase Ib GALACTA Trial

Acetaminophen Caused Transfusion Dependent Children Repeated Hepatitis

Activity and Safety of Daratumumab Monotheray in Patients with Relapsed and Refractory Multiple Myeloma Requiring Dialysis: Preliminary Results of Spanish, Retrospective, Multicenter Trial

Phase 1 Clinical Trial of Adoptive Immunotherapy Using "Off-the-Shelf" Activated Natural Killer Cells (aNK) in Patients with Refractory/Relapsed Acute Myeloid Leukemia

Decreased Rates of Severe CRS Seen with Early Intervention Strategies for CD19 CAR-T Cell Toxicity Management

Rescue of a Terminally Ill Patient with Chemo-Refractory Acute Lymphoblastic Leukemia Carrying Bcr/Abl and TP53 Mutations Based on a 4th Generation CD19 Chimeric Antigen Receptor-Engineered T (CAR-T) Therapy

An Update On The Clinical Activity Of Resimmune, a Targeted Therapy Directed To CD3 Receptor, In Patients With Cutaneous T Cell Lymphomas--CTCL

Open-Label Bendamustine Combined with Rituximab for Treatment of Relapsed/Refractory Mantle-Cell Lymphoma: Efficacy and Safety Findings

Selective Splenic Artery Embolization for the Treatment of Thrombocytopenia and Hypersplenism in Paroxysmal Nocturnal Hemoglobinuria (PNH)

Risk Factors for Infectious Complications in Adults with Acute Myeloid Leukemia Undergoing Induction Chemotherapy

Effects of Imatinib on the Pharmacokinetics of Acetaminophen in Korean Patients with Chronic Myelogenous Leukemia (CML)

Activity and Safety of Combined Fludarabine and Alemtuzumab Followed by Low-Dose Alemtuzumab Maintenance Therapy in Patients with B-CLL.

Combined Schedule of Fludarabine and Alemtuzumab Followed by Maintenance with Low-Dose Alemtuzumab Is Effective for Patients with Progressive B-Cell Chronic Lymphocytic Leukemia.

Interaction between Paracetamol and Warfarin: A Double-Blind Placebo-Controlled Randomised Study.

Chimeric Anti CD-20 Monoclonal Antibody-Rituximab in Refractory Childhood Idiopathic Thrombocytopenic Purpura: An Indian Experience.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only